

**Japan CAR-T Cell Therapy Market, By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others), By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others), By Treatment Type (Single Treatment, Combination Treatment), By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others) By Region, Competition, Forecast & Opportunities, 2019-2029F.**

<https://marketpublishers.com/r/JA46F0FBD340EN.html>

Date: October 2023

Pages: 81

Price: US\$ 3,500.00 (Single User License)

ID: JA46F0FBD340EN

## Abstracts

Cancer remains a significant health challenge, prompting the need for innovative treatment approaches. Among these groundbreaking therapies, Chimeric Antigen Receptor T-cell (CAR-T) therapy stands out as a revolutionary option. CAR-T therapy has gained immense attention in Japan due to its ability to utilize the patient's own immune system to target and eliminate cancer cells.

CAR-T cell therapy is a form of immunotherapy that involves modifying a patient's own

T-cells to express chimeric antigen receptors on their surface. These receptors are designed to recognize specific proteins on the surface of cancer cells. Once infused back into the patient, these modified CAR-T cells can effectively target and eliminate cancer cells that display the recognized antigens. This personalized treatment approach shows promising results, especially in patients with relapsed or refractory hematologic malignancies.

The introduction of CAR-T cell therapy has opened new avenues in cancer treatment within Japan. The Japanese CAR-T cell therapy market has experienced significant growth due to its potential as a curative treatment option for patients who have exhausted other available treatments. Regulatory changes, such as the revision of Japan's Pharmaceuticals and Medical Devices Act in 2014, have facilitated expedited approvals for regenerative medical products, including CAR-T therapies.

Collaborations between international biopharmaceutical companies and Japanese pharmaceutical firms have accelerated the development, production, and distribution of CAR-T therapies. Additionally, ongoing clinical trials evaluating the safety and efficacy of CAR-T cell therapy for various cancer types have contributed to building a strong body of evidence supporting its use in the Japanese population.

### Key Market Drivers

**High Incidence of Hematological Cancers:** Hematological cancers, such as leukemia, lymphoma, and myeloma, have been a significant health concern in Japan. The emergence of CAR-T therapy offers renewed hope for patients battling these diseases.

**Rising Healthcare Expenditure:** Japan's increasing healthcare expenditure, driven by an aging population and higher medical costs, has created a favorable environment for adopting advanced treatments like CAR-T cell therapy.

### Key Market Challenges

**High Costs:** The personalized nature and complex manufacturing process of CAR-T therapy result in high production costs, raising concerns about accessibility and affordability for patients.

**Infrastructure and Logistics:** Specialized infrastructure and logistical considerations are required for CAR-T therapy production, storage, and administration.

**Patient Eligibility Criteria:** Identifying suitable patients based on eligibility criteria and disease progression is crucial to maximize the benefits of CAR-T therapy.

**Long-Term Safety and Efficacy:** Continuous monitoring of patients treated with CAR-T therapy is essential to assess its long-term safety, efficacy, and potential side effects.

### Key Market Trends

**Technological Advancements:** Innovations in cell culture techniques, bioreactors, and data analytics have improved the scalability and efficacy of CAR-T therapy production. Japan's scientific research capabilities and regulatory support contribute to its leadership in the field.

### Segmental Insights

**Drug Type Insights:** Yescarta (Axicabtagene Ciloleucel) has emerged as a pioneering CAR-T therapy for treating large B-cell lymphomas, offering patients significant remission and potential long-term benefits.

**Tumor Type Insights:** Hematological malignancies dominate the CAR-T therapy market in Japan due to their prevalence and the limited treatment options available for patients with relapsed or refractory disease.

### Regional Insights

Hokkaido has become a leader in the Japan CAR-T Cell Therapy Market due to its concentration of expertise, research institutions, clinical trials, and specialized medical infrastructure.

In conclusion, CAR-T cell therapy represents a groundbreaking treatment option for hematological cancers in Japan. The market's growth is driven by high disease incidence, rising healthcare expenditure, and technological advancements. However, challenges related to cost, infrastructure, patient eligibility, and long-term safety must be addressed to fully harness the potential of CAR-T therapies. The concentration of expertise in regions like Hokkaido contributes to the growth and advancement of this innovative therapy in Japan.

### Key Market Players

Merck & Co., Inc.

Novartis AG

Pfizer, Inc.

Johnson & Johnson KK

Bristol-Myers Squibb

Gilead Sciences

#### Report Scope:

In this report, the Japan CAR-T Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

#### CAR-T Cell Therapy Market, By Product Type:

Yescarta (Axicabtagene Ciloleucel)

Kymriah (Tisagenlecleucel)

Tecartus (Brexucabtagene Autoleucel)

Breyanzi (Lisocabtagene Maraleucel)

Abecma (Idecabtagene Vicleucel)

Others

#### CAR-T Cell Therapy Market, By Tumor Type:

Hematological Malignancies

Solid Tumors

CAR-T Cell Therapy Market, By Indication:

Diffused Large B-Cell Lymphoma (DLBCL)

Acute Lymphoblastic Leukemia (ALL)

Follicular Lymphoma (FL)

Mantle Cell Lymphoma (MCL)

Others

CAR-T Cell Therapy Market, By Treatment Type:

Single Treatment

Combination Treatment

CAR-T Cell Therapy Market, By Targeted Antigen:

CD 19

BCMA (B-Cell Maturation Antigen)

Others

CAR-T Cell Therapy Market, By End User:

Hospitals

Specialty Clinics

Ambulatory Surgical Centers

Others

CAR-T Cell Therapy Market, By Region:

Hokkaido

Chubu

Chugoku

Kyushu.

## Competitive Landscape

**Company Profiles:** Detailed analysis of the major companies present in the Japan CAR-T Cell Therapy Market.

## Available Customizations:

Japan CAR-T Cell Therapy Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

## Company Information

Detailed analysis and profiling of additional market players (up to five).

## Contents

### 1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### 2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

### 3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

### 4. JAPAN CAR-T CELL THERAPY MARKET OUTLOOK

- 4.1. Market Size & Forecast
  - 4.1.1. By Value
- 4.2. Market Share & Forecast
  - 4.2.1. By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others)
  - 4.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
  - 4.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)

- 4.2.4. By Treatment Type (Single Treatment, Combination Treatment)
- 4.2.5. By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others)
- 4.2.6. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
- 4.2.7. By Region
- 4.2.8. By Company (2022)
- 4.3. Product Market Map

## **5. CHUBU CAR-T CELL THERAPY MARKET OUTLOOK**

- 5.1. Market Size & Forecast
  - 5.1.1. By Value
- 5.2. Market Share & Forecast
  - 5.2.1. By Product Type
  - 5.2.2. Tumor Type
  - 5.2.3. By Indication
  - 5.2.4. By Treatment Type
  - 5.2.5. By End User

## **6. CHUGOKU CAR-T CELL THERAPY MARKET OUTLOOK**

- 6.1. Market Size & Forecast
  - 6.1.1. By Value
- 6.2. Market Share & Forecast
  - 6.2.1. By Product Type
  - 6.2.2. Tumor Type
  - 6.2.3. By Indication
  - 6.2.4. By Treatment Type
  - 6.2.5. By End User

## **7. KYUSHU CAR-T CELL THERAPY MARKET OUTLOOK**

- 7.1. Market Size & Forecast
  - 7.1.1. By Value
- 7.2. Market Share & Forecast
  - 7.2.1. By Product Type
  - 7.2.2. Tumor Type
  - 7.2.3. By Indication
  - 7.2.4. By Treatment Type
  - 7.2.5. By End User



## **8. MARKET DYNAMICS**

- 8.1. Drivers
- 8.2. Challenges

## **9. MARKET TRENDS & DEVELOPMENTS**

- 9.1. Research & Development
- 9.2. Product launch
- 9.3. Merger & Acquisition

## **10. POLICY AND REGULATORY LANDSCAPE**

## **11. JAPAN CAR-T CELL THERAPY MARKET: SWOT ANALYSIS**

## **12. PORTER'S FIVE FORCES ANALYSIS**

## **13. PESTLE ANALYSIS**

## **14. COMPETITIVE LANDSCAPE**

- 14.1. Business Overview
- 14.2. Product Offerings
- 14.3. Recent Developments
- 14.4. Financials (In Case of Listed Companies)
- 14.5. Key Personnel
  - 14.5.1. Merck & Co., Inc.
  - 14.5.2. Novartis AG
  - 14.5.3. Pfizer, Inc.
  - 14.5.4. Johnson & Johnson KK
  - 14.5.5. Bristol-Myers Squibb
  - 14.5.6. Gilead Sciences

## **15. STRATEGIC RECOMMENDATIONS**

## 16. ABOUT US & DISCLAIMER

## I would like to order

Product name: Japan CAR-T Cell Therapy Market, By Product Type (Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), Tecartus (Brexucabtagene Autoleucel), Breyanzi (Lisocabtagene Maraleucel), Abecma (Idecabtagene Vicleucel), Others), By Tumor Type (Hematological Malignancies, Solid Tumors), By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others), By Treatment Type (Single Treatment, Combination Treatment), By Targeted Antigen (CD 19, BCMA (B-Cell Maturation Antigen), Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others) By Region, Competition, Forecast & Opportunities, 2019-2029F.

Product link: <https://marketpublishers.com/r/JA46F0FBD340EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/JA46F0FBD340EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970